Background: Human papillomaviruses (HPV) types 16 and 18 are clearly involved in the etiology of cervical cancer, but the evidence for the carcinogenicity of other HPV types is limited. Cofactors involved in the progression from infection with HPV to high-grade precursors and cancer have not been clearly defined by the results of previous studies. Methods: We conducted a hospital-based, case-control study of invasive cervical cancer to investigate risk in relation to HPV infection and its epidemiologic cofactors in Hat-Yai, Thailand. A total of 338 patients with squamous cell carcinoma, 39 patients with adenocarcinoma/adenosquamous carcinoma, and 261 control subjects were included in the study and were interviewed to obtain information with regard to cervical cancer risk factors. HPV DNA presence in cervical exfoliated cells or frozen biopsy specimens was determined by a polymerase chain reaction assay. Results: HPV DNA was detected in 95% of patients with squamous cell carcinoma, 90% of those with adenocarcinoma/adenosquamous carcinoma, and 16% of control subjects. For patients with squamous cell carcinoma, the most common types of HPV found were type 16 (60% of the positives), type 18 (18%), type 58 (3%), type 52 (3%), and type 31 (2%). For patients with adenocarcinoma/adenosquamous carcinoma, the most common HPV types found were type 18 (60% of the positives), type 16 (37%), and type 45 (3%). The risk factors that remained associated with risk of both
Several types of human papillomavirus (HPV), particularly types 16 and 18, are recognized as the main cause of cervical cancer and its precursor lesions (1) . These two viral types were found in more than 60% of a large series of cases of invasive cervical cancers reported from 22 countries around the world (2) . In that study, in all areas investigated, except Indonesia, HPV16 predominated in squamous cell carcinomas, whereas HPV18 often predominated in adenocarcinomas (2) (3) (4) . Other viral types have been detected in cervical cancers, but no case-control studies have adequately investigated typespecific associations with risk to classify these other types as definite carcinogens (1) . In addition, HPV infection appears to be a necessary but not a sufficient cause of cervical cancer, but the role of specific viral, host, or environmental factors for progression from infection to invasive disease has not been clarified.
When designing vaccine strategies or incorporating HPV testing in screening programs, it will be helpful to know the specific types of HPV operating as cervical carcinogens in different regions in order to know whether it is necessary to tailor interventions to the specific needs of particular areas. The definition of cofactors can help identify groups at particularly higher risk and can lead to new preventive strategies. To better define these issues, the International Agency for Research on Cancer (IARC) is conducting a series of case-control studies in several regions of the world, ensuring standardized epidemiologic methods and centralized polymerase chain reaction (PCR)-based HPV detection.
In this report, we present results from one of the studies conducted in the district of Hat-Yai, Province of Songkla in the south of Thailand, an area with an estimated age-adjusted incidence rate of cervical cancer of 18.5 per 100 000 women (5) .
Subjects and Methods

Study Population
Recruitment of study subjects was conducted from September 1990 through March 1993. Case subjects were women with invasive cervical cancer that was newly diagnosed and histologically or cytologically confirmed at the participating hospital in Hat-Yai. These subjects had not received previous treatment for cervical cancer, and all were in a sufficiently good physical and mental condition to provide reliable answers. Histologic and cytologic slides were reviewed by an expert pathologist (M. Santamaria). Control subjects were women without cervical cancer who were selected from the same hospital as the case subjects; these women were without histories of treatment with conization or hysterectomy and were broadly stratified by age (in 10-year groups) to the expected distribution of the case subjects. In addition, as was required for the case subjects, control subjects had to be in sufficiently good physical and mental condition to provide reliable answers. Other reasons for ineligibility of control subjects included diagnoses of anogenital tract cancers (vulva, vagina, or rectum), cancer of the breast, endometrium, ovary, or colon, benign genital tumors, and tobacco-related diseases (e.g., coronary heart disease, lung cancer, or chronic bronchitis).
The main diagnostic categories for the 354 control subjects originally recruited for the study were as follows: diseases of the digestive system (n ‫ס‬ 89; 25%); endocrine, nutritional, or metabolic disorders (n ‫ס‬ 83; 23%); diseases of the genitourinary system (n ‫ס‬ 55; 16%); nongenital neoplasms (n ‫ס‬ 33; 9%); and diseases of the circulatory system (n ‫ס‬ 24; 7%). Cytologic specimens were available from 331 (94%) of the control subjects; their diagnoses, which were not used as a criterion for exclusion, were normal (n ‫ס‬ 233; 70%), inflammatory or reactive (n ‫ס‬ 91; 28%), and cervical neoplasia (n ‫ס‬ 7; 2%), including one suspicious of adenocarcinoma.
Data and Specimen Collection
Each participant was administered a standardized questionnaire on sexual behavior, reproductive history, contraceptive practices, smoking habits, genital hygiene, histories of sexually transmitted diseases, cervical cytologic screening histories, and socioeconomic status. Face-to-face interviews were conducted by three different specially trained interviewers. An effort was made to keep the interviewers unaware of the case-control status of the study participants. Interviews lasted, on average, 30 minutes, but they were longer for case subjects (33.4 minutes) than for control subjects (25.7 minutes).
A pelvic examination was performed on case subjects and control subjects to obtain exfoliated cells for the preparation of a Pap smear and determination of the presence of HPV. The material was collected by sampling the ectocervix with a wooden spatula and the endocervix with a cytobrush; the procedure was performed in duplicate. The collection instruments were rinsed in phosphate-buffered saline (PBS), and the cell suspension was centrifuged for 10 minutes at 2000 rpm and room temperature. The cell pellets were stored at −70°C in the field until they were shipped to Lyon, France, or to Amsterdam, The Netherlands, for testing. From case subjects, tumor biopsy specimens were also collected and frozen immediately at −70°C.
Ethical committees at IARC and in Thailand approved the protocols, and written informed consent was obtained from all subjects. A total of 386 (98%) of the eligible case subjects and 354 (49%) of the eligible control subjects were interviewed. Refusal to participate was the main reason for nonparticipation of control subjects.
The final diagnosis was defined by histologic review of specimens from 350 (91%) case subjects. Because histologic slides were not provided for the remaining 36 (9%), a diagnosis was reached by review of the cytologic materials (n ‫ס‬ 7) or by reliance on local histologic diagnosis (n ‫ס‬ 29). Cancers in the case subjects were classified as follows: squamous cell carcinoma (n ‫ס‬ 345), adenocarcinoma (n ‫ס‬ 35), and adenosquamous carcinoma (n ‫ס‬ 6). The latter two groups were combined for analysis. Information on stage of the tumors (6) was available for more than 99% (n ‫ס‬ 385) of the case subjects, and stage distributions were as follows: 24% stage I, 43% stage II, 27% stage III, and 5% stage IV. Adenocarcinomas/adenosquamous carcinomas tended to be diagnosed at earlier stages; 45% of them were diagnosed at stage I.
On the basis of the degree of nuclear and architectural abnormalities and the proportion of cells showing cytoplasmic differentiation (squamous and glandular), the 355 carcinomas for which evaluable materials were available were graded as follows: well differentiated (n ‫ס‬ 150; 42%), moderately well differentiated (n ‫ס‬ 131; 37%), and poorly differentiated (n ‫ס‬ 74; 21%). Adenocarcinomas/adenosquamous carcinomas tended to be better differentiated; 70% of them were reported to be well differentiated. The presence of inflammatory cells and the number of mitoses per field were also recorded.
For five of the 386 case subjects, we did not have exfoliated cells or biopsy material for determination of HPV; those case subjects were excluded from this analysis. An additional four case subjects were excluded because of inadequate samples (␤-globin negative; see below). Because one batch was lost during shipment, exfoliated cells were not available for 63 control subjects, who were consequently excluded. An additional 30 control subjects who were ␤-globin negative and HPV DNA negative were also excluded. Thus, the final group consisted of 377 case subjects (338 squamous cell carcinomas and 39 adenocarcinomas/adenosquamous carcinomas) and 261 control subjects.
Detection of HPV DNA
HPV DNA detection on cervical scrape specimens was performed by PCR (7) . To analyze the quality of target DNA for PCR purposes, we prescreened scrapes by PCR with the use of ␤-globin gene-specific primers (8) . Scrapes that showed successful amplification of ␤-globin sequences were subjected to HPV DNA genotyping, which was carried out as follows: Briefly, a first screening to determine the overall presence of HPV was performed by use of general primer GP5+/6+-mediated PCR, which permits the detection of a broad spectrum of sequenced and still-unsequenced genital HPV types at the subpicogram level (9) . HPV positivity was assessed by low-stringency Southern blot analysis of PCR products with a cocktail probe of HPV-specific DNA fragments (10) . Subsequently, GP5+/6+-mediated PCR was performed in triplicate on positive samples to generate sufficient products for further typing. PCR products from independent reactions were pooled to generate identical Southern blots for parallel and successive hybridization rounds for typing with the use of internal typespecific oligoprobes (11) . The strategy of melting and rehybridization of the filters was essentially the same as that described earlier (12) . The first hybridization round was performed for HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, and 56. The second round included HPV types 6, 11, 26, 34, 40, 42, 43, 44, 58, 59 , and 68. The third round was performed for HPV types 57, 61, 66, 70 (equivalent to CP141-7), 72 (equivalent to CP4137), 73 (equivalent to MM9), IS39 and MM4 (related to HPV51), MM7, CP6108, and CP8304. The latter three are phylogenetically related to the low-risk HPV61 and HPV62 (8, 10) . Type-specific oligonucleotides (30-mers) were selected on the basis of sequence information from the HPV sequence database (13, 14) after alignment analysis with the CLUSTAL program (PC/ Gene, Release 6.7; Intelligenetics, Inc., Mountain View, CA) (15) .
Samples that were still GP5+/6+ positive and could not be identified by the above-mentioned probes were considered as HPV X.
In a second step, for those specimens found to be ␤-globin PCR negative as well as HPV PCR negative, DNA was extracted from the cell pellets and retested for HPV DNA as described above. In addition, for those cervical cancer case subjects from whom not enough cell pellet was available (␤-globin negative) as well as for those testing negative for HPV in the exfoliated cells despite an adequate specimen, the HPV DNA analysis was done on the corresponding biopsy specimens. For HPV DNA detection in the biopsy specimen, the sandwich method (i.e., snap-frozen tissues were cut in a way that the outer sections of a series of sections were used for histologic analysis and the inner sections were used for PCR testing) was used in which the quality of the tissue was controlled as described earlier (16) .
We took special precautions to minimize falsepositive results in the PCR, as has been described in detail elsewhere (10) .
Statistical Analysis
For the estimation of the risk of cervical cancer associated with HPV types and the other variables, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as approximations of relative risks by use of unconditional logistic regression (17) . Adjustment for potential confounders was performed by use of this method. The ORs associated with HPV were adjusted only for age (categorized in four age groups: <40 years, 40-49 years, 50-59 years, and ജ60 years) because adjustment for all other relevant risk factors did not materially change the estimates. ORs are presented only for HPV types detected in at least four case subjects. For the analysis of other risk factors, a model including the main variables significantly associated with risk in the univariate model and related to the hypotheses under evaluation was prepared. For the analysis of cofactors of HPV, a model restricted to the HPV-positive case subjects and control subjects was designed; it also included adjustment for all the relevant risk factors.
An initial comparison of case subjects and control subjects revealed that case subjects were more likely than control subjects to be residents of provinces other than the province of the participating hospital, raising the possibility of selection bias. Therefore, the effect of place of residence was examined in the analysis, but it was later removed from the final model because risk estimates changed only minimally when place of residence was included.
HPV attributable fractions (AFs) have been calculated according to standard methods, AF ‫ס‬ p(r − 1)/[1 + p(r − 1)], where p ‫ס‬ HPV DNA prevalence in the population approximated by the prevalence in the control group and r ‫ס‬ relative risk approximated by the OR.
Statistical significance was tested by use of the likelihood ratio test for the difference for dichotomous variables and for two-sided linear trend for variables with logically ordered categories.
Results
The mean age for patients with squamous cell carcinoma was 50.3 years; for patients with adenocarcinoma/adenosquamous carcinoma, it was 46.1 years; for control subjects, it was 49.7 years. In the final group, case subjects and control subjects were distributed similarly by age group, religion, church attendance, and residence in urban versus rural areas.
Overall prevalence of HPV detection among case subjects was 95% for those with squamous cell carcinoma and 90% for those with adenocarcinoma/adenosquamous carcinoma and did not vary substantially according to demographic characteristics or exposure to different risk factors. Among control subjects, overall HPV prevalence in exfoliated cells was 16% and was associated inversely with age, with a positivity of 20% among women under age 35 that decreased consistently with age to 6% in the group 65 years old or older (P for trend ‫ס‬ .13). A slight tendency toward increasing positivity was observed with increasing education (P for trend ‫ס‬ .29), but there was no association with age at first intercourse or number of sexual partners, although in this population very few women reported three or more sexual partners, a group in whom the prevalence of HPV detection was 0.
Sixteen different HPV types were detected in specimens of squamous cell carcinoma (Table 1) , four were found in specimens of adenocarcinoma/adenosquamous carcinoma, and 10 were found in specimens from control subjects. The fraction of risk attributable to HPV in the population was 95% for squamous cell carcinomas and 89% for adenocarcinomas/adenosquamous carcinomas. Table 3 presents ORs associated with squamous cell carcinoma risk factors other than HPV. In univariate analysis (age-adjusted), the following factors were associated with risk: increasingly limited education, decreasing age at first intercourse, increasing number of live births, number of lifetime sexual partners, history of venereal disease, use of hormonal contraceptives for longer than 4 years, and ever smoking. In addition, a history of previous cytologic screening was associated with a substantial reduction in risk after exclusion of examinations done in the year before diagnosis for the case subjects and date of interview for the control subjects. After adjustment for the presence of HPV DNA in the cervix and for the mutual confounding effect of the other variables, the association with education became not significant (P for trend ‫ס‬ .13). The variables that remained associated with risk were number of lifetime sexual partners (P for trend ‫ס‬ .003), history of increasing number of episodes of venereal diseases (P for trend ‫ס‬ <.001), *Based on results from exfoliated cells and biopsy specimens in case subjects and exfoliated cells only in control subjects. Percentage of HPV types are calculated relative to the total HPV positive and indicates percentage of positive cases in which a specific type alone or in combination was detected. The total percentage of a specific HPV type requires the addition of case subjects in which it appears in combination with other types.
†Beginning with the fourth value in this column (i.e., 24.4), all percentages reflect the percent of HPVpositive control subjects. and interval since last Pap smear (P for trend ‫ס‬ .005). When compared with women reporting only one lifetime sexual partner, those reporting two had a 2.5-fold and those reporting three or more had a sevenfold increase in risk. Women who reported having had any venereal disease once had a 2.2-fold increase in risk compared with women who reported never having had venereal diseases, and those who reported more than one episode of venereal disease had a 4.7-fold increase in risk. All the venereal diseases reported (syphilis, gonorrhea, genital warts, herpes genitalis, parasites, and ''other'') were more common in case subjects than in control subjects, but the most frequently reported was parasites. When compared with women who were never screened, those who were screened 5 or more years before the interview had a 40% reduction in risk, but those who were screened in the previous 5 years had a 70% reduction in risk. When this analysis was restricted to the HPV-positive case subjects and control subjects, the same associations persisted, but smoking again appeared to be associated with a 2.8-fold increase in risk of squamous cell carcinoma. However, no clear evidence of a doseresponse effect with amount or duration of smoking was evident. Table 4 presents risk factors other than HPV for adenocarcinoma/adenosquamous carcinoma. A very similar pattern of association with the different risk factors was observed, with increases in risk remaining after adjustment for limited education, number of sexual partners, histories of venereal diseases, and some effect of smoking. None of the trends in the adjusted model were, however, statistically significant given the relatively small numbers. In the HPV-positive strata, similar magnitudes of risk were detected for number of sexual partners and histories of venereal diseases, but no associations were observed with smoking.
Discussion
The results of this case-control study conducted in Thailand confirm the findings of other investigators (1) indicating that HPV DNA is present in the vast majority of cervical cancers, regardless of histology. In this investigation, HPV DNA was detected in 95% of squamous cell carcinomas and 90% of adenocarcinomas/adenosquamous carcinomas. This high prevalence of detection of HPV in cervical tumors, now frequently observed in studies applying PCR methods for detection of HPV, casts doubt on the existence of HPV-negative cervical cancer (18) .
There are several possible explanations for why some case subjects were scored HPV DNA negative. For example, the biopsy specimen may not have been representative of the tumor tissue or the HPV DNA could have been interrupted by integration in the host cell DNA, thereby deleting the L1 region that was the target of the PCR used. Other possibilities are the existence of still new HPV types or the presence of HPV types amplifying less efficiently in low copy number (e.g., HPV39 or HPV52).
To ensure that the biopsy specimens on which the PCR was performed were representative of the tumor tissue, we used the sandwich method of sample preparation (16) , in which histologic verification of the specimens is carried out. In fact, in some HPV DNA-negative case subjects, the histology was poor and the diagnosis of cancer could not be confirmed in the frozen specimens.
The PCR method that we used is considered highly sensitive (10) . Moreover, the strategy used for typing has been tested before (12) , indicating that three rounds of melting and rehybridization of the filters do not affect the sensitivity of the assay. Therefore, eventual underrepresentations of HPV types tested in this study are unlikely to be the result of the typing methodology.
Our results with respect to prevalence of HPV by age in the control group agree with previous observations (1) of declining prevalence of infection with increasing age. In this study, the decline did not appear to be as dramatic in the younger ages as has been observed in another study (19) , but prevalence declined from approximately 20% among women under 35 years of age to approximately 6% among women older than 65 years. HPV16 was the most common HPV type in squamous cell carcinoma (60% of the positives), followed by HPV18 (18%). The overall OR for cervical cancer associated with HPV positivity by any HPV type was 119, and strong associations with risk of squamous cell carcinoma were observed for the eight most common HPV types found in this population (types 16, 18, 31, 33, 45, 52, 58, and 59). In adenocarcinomas/adenosquamous carcinomas, HPV18 was the most common type found (60% of the positives), followed by HPV16 (37%). A more limited number of HPV types was found for this histologic type. Apart from very strong associations with HPV16 and HPV18, the only other type associated with increased risk of adenocarcinoma/adenosquamous carcinoma of the cervix was HPV45.
Although several case series that used PCR-based assays have reported HPV DNA in substantial proportions of adenocarcinomas (1), to our knowledge, this is one of the first case-control studies (20) in which the risk linked to specific HPV types has been estimated for adenocarcinoma/adenosquamous carcinoma. Our results confirm that, as was found for squamous cell carcinoma, HPV types 18, 16, and 45 (in order of strength of association) are the main causes of adenocarcinoma/adenosquamous carcinoma.
HPV positivity among case subjects was different when only exfoliated cells or exfoliated cells and biopsy specimens were evaluated (83% versus 95% in squamous cell carcinomas and 84% versus 90% in adenocarcinomas/adenosquamous carcinomas), and from control subjects we had results only from the analysis of exfoliated cells. Thus, the ORs that we present are higher than those obtained when only exfoliated cells from both case and control subjects are tested. However, we consider this to be a valid approach because we have conducted extensive retesting of specimens in our large series of patients with invasive cancer who were from 22 countries (2), and preliminary unpublished results (Walboomers JMM, Jacobs MV, Manos MM, Muñoz N, Bosch FX, Kummer A) indicate that HPV is detectable in almost 99% of the case subjects. In this context, we observed in this study that undifferentiated tumors and tumors with high number of mitoses had significantly lower HPV detection rates when exfoliated cells were analyzed than when results from cells and biopsy specimens (74% versus 94%) were included, whereas well-differentiated tumors with few mitoses had similar prevalence (90% versus 94%) (data not shown), indicating that the more undifferentiated cancers may have a limited ability to exfoliate (i.e., detach and shed superficial cells) cells with detectable HPV DNA. This association of HPV positivity with degree of differentiation could be an indirect indication that, among control subjects, exfoliated cells may suffice to provide a reliable estimate of the presence of HPV DNA. To resolve the issue of possible bias in the ORs calculated, we are conducting a sampling validation study in which cells and biopsy specimens have been collected from normal cervices of women undergoing hysterectomy for reasons other than cancer. Preliminary analysis of this study indicates that the prevalence of HPV positivity is almost identical when exfoliated cell results are used to that obtained with biopsy specimens (data not shown). Investigation of cofactors in this analysis revealed statistically significant associations with the number of sexual partners and histories of venereal disease as well as an association with smoking that was restricted to squamous cell carcinomas. These associations were evident even when the analysis was restricted to HPV-positive women, which practically eliminated the possibility of this being the result of residual confounding by HPV. The association with increasing number of sexual partners may be related to transmission in this population of other sexually transmitted agents that can act as cofactors of HPV. This hypothesis is supported by the high frequency of reported histories of venereal diseases among both case subjects and control subjects and its strong association with risk. Without additional data, it is hard to point to a specific sexually transmitted agent, since most of this association was driven by the effect of parasites, which is obviously an indirect marker. However, all other sexually transmitted diseases were also associated with risk. We are currently investigating the role of chlamydia and herpes simplex virus type II in serologic specimens in this population. A recently published case-control study in Thailand (21) indicated a high prevalence of histories of visits to prostitutes among Thai males. It is of interest that, in our study, risk factors were similar for squamous cell carcinomas and adenocarcinomas/ adenosquamous carcinomas, with the exception of smoking, which appears to play a role only in squamous cell carcinomas. On the other hand, the associations with age at first intercourse, number of live births, and use of hormonal contraceptives disappeared after adjustment. The results of other published case-control studies of invasive cancer (22) (23) (24) , including our companion report (20) , have found strong, independent associations with some of these variables, but the pattern is not consistent, indicating the possibility of different cofactors playing a role in different areas and the need for further research. Potential limitations should be considered in the interpretation of our results. Our study was hospital based; as such, it may suffer from selection bias. The case subjects were consecutive incident case subjects attending the largest hospital in Hat-Yai, and most of them agreed to participate. The control subjects were attending the same hospital, and it can be assumed that they came from the same population as the case subjects. The fact that all case subjects were hospitalized with a variety of diseases, some of which were infectious, could theoretically increase the prevalence of HPV in the control group if some had an impaired immune status. However, this would only underestimate our relative risks associated with HPV. The refusal rate for control subjects was very high (50%), and 60 control specimens were lost during shipment. In addition, 30 control specimens had to be excluded because they were ␤-globin negative. Given this important loss of control subjects, we cannot exclude the possibility of selection bias. However, the prevalence of HPV in the control group was higher than that reported in other studies, suggesting that, if there is selection bias, it could have led to an underestimation of the relative risk associated with HPV. On the other hand, the final group of control subjects was similar to the case subjects in age, ethnicity, and religion, suggesting a nondifferential loss of control subjects. Another potential limitation is that we had small numbers of case subjects with some of the HPV types, which can add uncertainty to the magnitude of risk associated with some of the unusual HPV types.
In summary, HPV DNA appears to play a carcinogenic role in almost all squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix in Thailand, as was found elsewhere. HPV types 16, 18, 31, 33, 45, 52, 58, and 59 are particularly involved in the etiology of squamous cell carcinomas, and HPV types 16, 18, and 45 are associated with adenocarcinomas/adenosquamous carcinomas. The fact that a limited number of HPV types are emerging as responsible for the majority of cervical cancers in most geographic areas will facilitate the introduction of globally useful control strategies, based on HPV vaccines. In this population, in particular, other yet unidentified sexually transmitted agents are likely cofactors of HPV. Background: Recent evidence suggests that folic acid (and derivatives) could contribute to the protective effect of fruits and vegetables against the risk of large-bowel cancer. Other evidence indicates that alcohol drinking and cigarette smoking may impair the biologic actions of folate. We used data from an adenoma prevention trial to investigate the occurrence of colorectal adenomas (possible precursors of colorectal cancer) in association with folate intake, alcohol consumption, and cigarette smoking. Methods: Patients with at least one recent large-bowel adenoma were followed with colonoscopy 1 year and 4 years after their qualifying colon examinations. Adenomas detected after the year 1 examination were used as end points. A food-frequency questionnaire was administered at study entry and at study completion; nutrient intake at study entry was used in this analysis. All statistical tests were twosided. Results: After adjustment for caloric intake, dietary folate had a significant protective association with the risk of recurrence of large-bowel adenoma (P for trend = .04). However, this inverse association was attenuated by further adjustment for intake of dietary fiber and fat. Use of folate supplements was not associated with a reduction in risk. Alcohol intake (seven or more drinks/week) was associated with increased risk (odds ratio = 2.04; 95% confidence interval = 1.28-3.26). Cigarette smoking, even smoking for long duration, was not related to adenoma recurrence. Conclusions: These data provide only modest support for previous findings suggesting beneficial effects of folate on colorectal adenoma risk. We find no evidence that cigarette smoking increases risk. These findings do suggest a substantial increase in risk with alcohol consumption. [J Natl Cancer Inst 1998;90:57-62]
An apparent protective effect of fruits and vegetables on the risk of cancer of the large bowel has been a consistent epidemiologic finding, but the food constituents that may have an anticarcinogenic effect have not been clearly identified (1) . Recent investigation has suggested that folate (folic acid and its derivatives such as tetrahydrofolate and 5-methyl-tetrahydrofolate) could contribute to such a protective effect. Folate-deficient rats demonstrate heightened sensitivity to carcinogens (2), and some epidemiologic studies (3) (4) (5) (6) (7) (8) (9) have reported that individuals with high folate intake have a reduced risk of colorectal cancer or colorectal adenomas. The mechanism by which folate might exert an anticarcinogenic effect is not clear but may relate to its role in DNA methylation (10) .
Cigarette smoking and alcohol intake are two common habits that may impair the biologic actions of folate. Ethanol and its metabolites appear to reduce circulating folate levels and to interfere with some of its biochemical actions (7). Alcohol intake has been associated with an increased risk of colorectal cancer (11, 12) . However, the results obtained from investigations on this point have not been consistent, and most epidemiologic studies have not shown a strong relationship (11, 12) . In contrast, alcohol intake is more clearly associated with the risk of large-bowel adenomas (13) .
Cigarette smoking also appears to have an antifolate effect. Smoking is associated with decreased circulating folate levels
